Skip to content
ESPT
MARKETS / NASDAQ / Health care / Pharmaceuticals / ALKS
NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP

Alkermes PLC. ALKS

17 fiscal years on record · USD · FY2025 reported · SEC filings only
$1.5B
▼ 5.2% YoY
$241.7M
▼ 34.2% YoY
$480.3M
▲ 18.4% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Alkermes plc has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy, and a pipeline of clinical and preclinical candidates in development for neurological disorders. ARISTADA is an extended-release intramuscular injectable suspension approved in the U.S. for the treatment of schizophrenia. VIVITROL is a once-monthly, non-narcotic, injectable medication approved in the U.S. for the treatment of alcohol dependence in patients able to abstain from alcohol in an outpatient setting prior to initiation of treatment, and for the prevention of relapse to opioid dependence following opioid detoxification. It manufactures ARISTADA, ARISTADA INITIO, LYBALVI, VIVITROL and microspheres for RISPERDAL CONSTA at its Wilmington, Ohio facility. It is headquartered in Ireland and also has a corporate office and R&D center in Massachusetts. As of February 20, 2026, it had approximately 2,050 full time employees, of which approximately 1,950 were based in the U.S. and approximately 100 were based in Ireland.

Written from the business description in Alkermes plc.'s annual report to the U.S. Securities and Exchange Commission, filed 25 February 2026. Every sentence was checked against that document before publication.

Growth

USD 1.5B
Revenue, FY2025 · full 17-year series below
Revenue $B Net income $B
FY2025 · Revenue 1.5 · Net income 0.2
1.0B2.0B-0.1B-0.2B
2009201220152018202120242025
Compound annual growth
+9.9%
+7.3%
+8.9%
+14.8%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +7.3% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

16 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 17.2% · Net 16.4%
10%20%-10%-20%-30%
200920172025
ROE
FY2025 · ROE 14.7%
10%20%30%-5%-10%-15%
200920172025
Three returns, three denominators.
Gross margin86.7%
Operating margin17.2%
Net margin16.4%
EBITDAUSD 281.1M

Each USD of equity produced 15 cents of profit this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 480.3
200M400M-50M-100M
200920172025
Net buybacks $M Dividends $M
FY2024 · Dividends · · Net buybacks 200.3
100M200M
20092024
Dividends paid·
Net buybacks·
Share of profit·
Consecutive raises·

Total assetsUSD 2.5B
EquityUSD 1.8B
CashUSD 388.6M
Current ratio3.55×

Equity funds 73% of total assets.

The 17-year record

17 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
ALKS, 17-year financial record
Metric 20252024202320222021202020192018201720162015201420132012201120102009
Revenue $B1.51.61.71.11.21.01.21.10.90.70.60.60.60.60.40.20.2
Operating income $B0.30.40.4−0.00.1−0.1−0.2−0.1−0.1−0.2−0.2−0.10.00.1−0.1−0.0−0.0
EBITDA $B0.30.40.50.10.2−0.0−0.10.0−0.0−0.1−0.10.0◌0.2−0.0−0.0−0.0
Income tax $B0.00.1−0.10.00.00.0−0.00.00.0−0.00.00.0−0.00.0−0.0−0.0−0.0
Net income $B0.20.40.4−0.2−0.0−0.1−0.2−0.1−0.2−0.2−0.2−0.00.00.0−0.1−0.0−0.0
Free cash flow $B0.50.40.4−0.00.10.0−0.00.0−0.0−0.1−0.1−0.0◌0.1−0.0−0.0−0.0
EPS, diluted $1.432.172.10−0.97−0.29−0.70−1.25−0.90−1.03−1.38−1.52−0.210.140.18−0.99−0.48−0.42
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend—————————————————
ROE %14.727.531.7−14.7−4.4−10.3−17.4−11.7−13.1−16.5−16.8−2.42.02.8−18.2−11.3−9.6
Shares out B0.170.160.170.160.160.160.160.160.150.150.150.150.140.000.000.10◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

MCK · COR · CAH · JNJ · HCA · LLY
Provenance

Company facts, as filed

How we verify · 0 failures in 66 reconciliationsAUDITED

Reconciled in 17 of the 17 fiscal years we could check. Six checks were skipped: the balance sheet is not tagged before 2010. Two checks were skipped: EPS is not tagged before 2009. Two checks were skipped: revenue is not tagged before 2009.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated innot stated in the filings
Fiscal year endsDecember 31
Data on record since2009

Share this section

Download image